Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a highly heterogeneous tumor. Molecular profiling serves as the foundation for personalized treatment of ICC. Comprehensive molecular testing is needed to identify more patients that are suitable for specific targeted therapies. This consensus is based on clinical data from both domestic and international sources, tailored to the Chinese context, and focuses on key targets for ICC. We present 15 recommendations aimed at guiding the precision detection of ICC.

Keywords

Intrahepatic cholangiocarcinoma / Precision detection / Biomarkers / Personalized treatment

References

[1] RumgayH, FerlayJ, de MartelC, GeorgesD, IbrahimAS, ZhengR, et al. . Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer, 2022, 161: 108-118.

[2] CongWM, DongH, TanL, SunXX, WuMC. Surgicopathological classification of hepatic space-occupying lesions: a single-center experience with literature review. World J Gastroenterol, 2011, 17: 2372-2378.

[3] AnL, ZhengR, ZhangS, ChenR, WangS, SunK, et al. . Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr, 2023, 12: 45-55.

[4] MorisD, PaltaM, KimC, AllenPJ, MorseMA, LidskyME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin, 2023, 73: 198-222.

[5] NishidaN, KudoM. Genetic/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: transforming the immune microenvironment with molecular-targeted agents. Liver Cancer, 2023, 13: 136-149.

[6] ZouS, LiJ, ZhouH, FrechC, JiangX, ChuJS, et al. . Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun, 2014, 5: 5696.

[7] DongL, LuD, ChenR, LinY, ZhuH, ZhangZ, et al. . Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell, 2022, 40: 70-87.e15.

[8] Bekaii-SaabTS, BridgewaterJ, NormannoN. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol, 2021, 32: 1111-1126.

[9] LinJ, CaoY, YangX, LiG, ShiY, WangD, et al. . Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics, 2021, 11: 4585-4598.

[10] KendallT, VerheijJ, GaudioE, EvertM, GuidoM, GoeppertB, et al. . Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int, 2019, 39Suppl 17-18.

[11] LoweryMA, PtashkinR, JordanE, BergerMF, ZehirA, CapanuM, et al. . Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res, 2018, 24: 4154-4161.

[12] KatohM. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol, 2019, 16: 105-122.

[13] NeumannO, BurnTC, AllgauerM, BallM, KirchnerM, AlbrechtT, et al. . Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer, 2022, 127: 1540-1549.

[14] ZouY, ZhuK, PangY, HanJ, ZhangX, JiangZ, et al. . Molecular detection of FGFR2 rearrangements in resected intrahepatic cholangiocarcinomas: FISH could be an ideal method in patients with histological small duct subtype. J Clin Transl Hepatol, 2023, 11: 1355-1367

[15] ZhangX, BaiQ, WangY, JiangZ, HanJ, XueC, et al. . FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH. Virchows Arch, 2025.

[16] PuXH, YeQ, YangJ, WuHY, DingXW, ShiJ, et al. . Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population. Hum Pathol, 2018, 76: 100-109.

[17] TianW, HuW, ShiX, LiuP, MaX, ZhaoW, et al. . Comprehensive genomic profile of cholangiocarcinomas in China. Oncol Lett, 2020, 19: 3101-3110

[18] JiangG, ZhangW, WangT, DingS, ShiX, ZhangS, et al. . Characteristics of genomic alterations in Chinese cholangiocarcinoma patients. Jpn J Clin Oncol, 2020, 50: 1117-1125.

[19] GalloLH, NelsonKN, MeyerAN, DonoghueDJ. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev, 2015, 26: 425-449.

[20] SilvermanIM, LiM, MurugesanK, KrookMA, JavleMM, KelleyRK, et al. . Validation and characterization of FGFR2 rearrangements in cholangiocarcinoma with comprehensive genomic pro filing. J Mol Diagn, 2022, 24: 351-364.

[21] GoyalL, Meric-BernstamF, HollebecqueA, ValleJW, MorizaneC, KarasicTB, et al. . Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med, 2023, 388: 228-239.

[22] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: biliary tract cancers (2024.V4). 2024. https://nccn.medlive.cn/guide/index.

[23] Guideline Working Committee of the Chinese Society of Clinical Oncology [In Chinese]Guidelines of Chinese Society of Clinical Oncology: biliary tract cancer, 2024BeijingPeople’s Health Publishing House

[24] ClearyJM, RaghavanS, WuQ, LiYY, SpurrLF, GuptaHV, et al. . FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov, 2021, 11: 2488-2505.

[25] SilvermanIM, HollebecqueA, FribouletL, OwensS, NewtonRC, ZhenHL, et al. . Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov, 2021, 11: 326-339.

[26] MoseleF, RemonJ, MateoJ, WestphalenCB, BarlesiF, LolkemaMP, et al. . Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol, 2020, 31: 1491-1505.

[27] BoscoeAN, RollandC, KelleyRK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol, 2019, 10: 751-765.

[28] MaB, MengH, TianY, WangY, SongT, ZhangT, et al. . Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer, 2020, 20: 318.

[29] WangL, ZhuH, ZhaoY, PanQ, MaoA, ZhuW, et al. . Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med, 2020, 18: 273.

[30] ZhuAX, MacarullaT, JavleMM, KelleyRK, LubnerSJ, AdevaJ, et al. . Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation. JAMA Oncol, 2021, 7: 1669-1677.

[31] Peraldo-NeiaC, ScatoliniM, GrossoE, LombardiP, FilippiR, RaggiC, et al. . Assessment of a high sensitivity method for identification of IDH1 R132x mutations in tumors and plasma of intrahepatic cholangiocarcinoma patients. Cancers, 2019, 11: 454.

[32] ClearyJM, RouaisnelB, DainaA, RaghavanS, RollerLA, HuffmanBM, et al. . Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. NPJ Precis Oncol, 2022, 6: 61.

[33] AgarwalS, SharmaMC, JhaP, PathakP, SuriV, SarkarC, et al. . Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol, 2013, 15: 718-726.

[34] XinHY, SunRQ, ZouJX, WangPC, WangJY, YeYH, et al. . Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma. JAMA Netw Open, 2023, 6: e231476.

[35] YaegerR, CorcoranRB. Targeting alterations in the RAF-MEK pathway. Cancer Discov, 2019, 9: 329-341.

[36] GoeppertB, FrauenschuhL, RennerM, RoesslerS, StenzingerA, KlauschenF, et al. . BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol, 2014, 27: 1028-1034.

[37] HardingJJ, Piha-PaulSA, ShahRH, MurphyJJ, ClearyJM, ShapiroGI, et al. . Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun, 2023, 14: 630.

[38] AyasunR, OzerM, SahinI. The role of HER2 Status in the biliary tract cancers. Cancers, 2023, 15: 2628.

[39] CaoJ, HuJ, LiuS, Meric-BernstamF, Abdel-WahabR, XuJ, et al. . Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients. JCO Precis Oncol., 2020, 4: PO.18.00414

[40] JavleM, BoradMJ, AzadNS, KurzrockR, Abou-AlfaGK, GeorgeB, et al. . Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol, 2021, 22: 1290-1300.

[41] Meric-BernstamF, MakkerV, OakninA, OhDY, BanerjeeS, González-MartínA, et al. . Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol, 2024, 42: 47-58.

[42] Biliary Tract Tumor Committee of Chinese Anti-Cancer Association, Biliary Tract Tumor Committee of Chinese Society of Clinical Oncology [In Chinese]. Chinese expert consensus on HER2 molecular diagnosis and clinical application of biliary malignant tumors (2024 edition). Chin J Pract Surg., 2024, 44: 1321-1327

[43] VaishnaviA, LeAT, DoebeleRC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov, 2015, 5: 25-34.

[44] MarchettiA, FerroB, PasciutoMP, ZampacortaC, ButtittaF, D’AngeloE. NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. Pathologica, 2022, 114: 199-216.

[45] XuY, ShiX, WangW, ZhangL, CheungS, RudolphM, et al. . Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. NPJ Precis Oncol, 2023, 7: 75.

[46] XuC, SiL, WangW, LiZ, SongZ, WangQ, et al. . Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Thorac Cancer, 2022, 13: 3084-3097.

[47] HabereckerM, TöpferA, MelegaF, MochH, PauliC. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types. Histopathology, 2023, 82: 1003-1012.

[48] LiAY, McCuskerMG, RussoA, ScillaKA, GittensA, ArensmeyerK, et al. . RET fusions in solid tumors. Cancer Treat Rev, 2019, 81: 101911.

[49] DukeES, BradfordD, MarcovitzM, AmatyaAK, Mishra-KalyaniPS, NguyenE, et al. . FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res, 2023, 29: 3573-3578.

[50] SubbiahV, CassierPA, SienaS, GarraldaE, Paz-AresL, GarridoP, et al. . Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med, 2022, 28: 1640-1645.

[51] YangSR, AyparU, RosenEY, MataDA, BenayedR, MullaneyK, et al. . A performance comparison of commonly used assays to detect RET fusions. Clin Cancer Res, 2021, 27: 1316-1328.

[52] ZhouSL, XinHY, SunRQ, ZhouZJ, HuZQ, LuoCB, et al. . Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg, 2022, 157: 59-65.

[53] AwadMM, LiuS, RybkinII, ArbourKC, DillyJ, ZhuVW, et al. . Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med, 2021, 384: 2382-2393.

[54] MarabelleA, LeDT, AsciertoPA, Di GiacomoAM, De Jesus-AcostaA, DelordJP, et al. . Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol, 2020, 38: 1-10.

[55] YangX, LianB, ZhangN, LongJ, LiY, XueJ, et al. . Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. BMC Med, 2024, 22: 42.

[56] KangSY, KimDG, AhnS, HaSY, JangKT, KimKM. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Pathol Res Pract, 2022, 233: 153874.

[57] NagasakaM, OuSI. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trend Cancer, 2022, 8: 242-258.

[58] TomczakA, SpringfeldC, DillMT, ChangDH, KazdalD, WagnerU, et al. . Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer, 2022, 127: 1701-1708.

[59] KimDW, SchramAM, HollebecqueA, NishinoK, MacarullaT, RhaSY, et al. . The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol, 2024, 20: 1057-1067.

[60] XuC, WangQ, WangD, WangW, FangW, LiZ, et al. . Expert consensus on the diagnosis and treatment of NRG1/2 gene fusion solid tumors. Glob Med Genet, 2024, 11: 86-99.

[61] DrilonA, DuruisseauxM, HanJY, ItoM, FalconC, YangSR, et al. . Clinicopathologic features and response to therapy of nrg1 fusion-driven lung cancers: the eNRGy1 global multicenter registry. J Clin Oncol, 2021, 39: 2791-2802.

[62] Tumor Marker Committee of Chinese Anti-Cancer Association, China Actionable Gene Consortium [In Chinese]. The expert consensus on the application of second-generation sequencing technology in precision medicine diagnosis of cancer. Natl Med J China., 2018, 98: 2057-2065

[63] Biliary Tract Tumor Committee of Chinese Anti-Cancer Association. CACA guidelines for targeted and immunotherapy of biliary tract malignancies (2024, summary edition). Chin J Pract Surg., 2024, 44: 970-983

[64] HuangYH, ZhangCZ, HuangQS, YeongJ, WangF, YangX, et al. . Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol, 2021, 74: 838-849.

[65] LamarcaA, KapaceeZ, BreezeM, BellC, BelcherD, StaigerH, et al. . Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med, 2020, 9: 2854.

[66] ModyK, KasiPM, YangJ, SurapaneniPK, Bekaii-SaabT, AhnDH, et al. . Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol, 2019, 3: 1-9.

[67] HwangS, WooS, KangB, KangH, KimJS, LeeSH, et al. . Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol, 2025, 82: 649-657.

[68] BerchuckJE, FacchinettiF, DiToroDF, BaievI, MajeedU, ReyesS, et al. . The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol, 2022, 33: 1269-1283.

[69] IsraelMA, DanzigerN, McGregorKA, MurugesanK, GjoerupO, SokolES, et al. . Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist, 2021, 26: 787-796.

[70] ZhangJ, ZhangX, WangQ, XuY, YaoQ, HuangD, et al. . Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression. J Cancer Res Clin Oncol, 2023, 149: 3423-3434.

Funding

Science and Technology Commission of Shanghai Municipality(22JC1403002)

RIGHTS & PERMISSIONS

The Author(s)